PMID- 37034211
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230411
IS  - 2156-6976 (Print)
IS  - 2156-6976 (Electronic)
IS  - 2156-6976 (Linking)
VI  - 13
IP  - 3
DP  - 2023
TI  - Local-regional therapy combined with toripalimab and lenvatinib in patients with 
      advanced biliary tract cancer.
PG  - 1026-1037
AB  - Local-regional therapy combined with PD-1 inhibitors and lenvatinib (triple 
      combination therapy) has demonstrated potent antitumor activity in solid tumors. 
      However, the efficacy and safety of the triple combination therapy in patients 
      with advanced biliary tract cancer (BTC) remain unclear. This retrospective study 
      evaluated the efficacy and safety of the triple combination therapy in advanced 
      BTC. Tumor tissues were collected to assess the expression status of PDL1 to 
      identify efficacy biomarkers. Forty-nine patients were included: 24 in lenvatinib 
      plus toripalimab therapy; 25 in the triple combination therapy. The triple 
      combination therapy group showed longer median progression-free survival (mPFS) 
      (7.9 versus 5.6 months, P=0.015) and longer median overall survival (mOS) (13.7 
      versus 11.1 months, P=0.145) than the lenvatinib plus toripalimab group. The 
      overall response rate (ORR) was 32% [95% confidence interval (CI): 12.3-51.7] 
      with the triple combination therapy versus 25% (95% CI: 6.3-43.7) with 
      toripalimab plus lenvatinib. Three patients received surgery after the triple 
      combination therapy. All patients experienced any-grade adverse events (AEs) 
      without any specific toxicities. PDL1 expression was associated with improved 
      clinical benefits. Local-regional therapy combined with PD-1 inhibitors and 
      lenvatinib may be an encouraging treatment choice for advanced BTC without an 
      increase in specific toxicities.
CI  - AJCR Copyright (c) 2023.
FAU - Wang, Yunchao
AU  - Wang Y
AD  - Department of Liver Surgery, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College Beijing 100730, 
      China.
FAU - Xun, Ziyu
AU  - Xun Z
AD  - Department of Liver Surgery, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College Beijing 100730, 
      China.
FAU - Yang, Xu
AU  - Yang X
AD  - Department of Liver Surgery, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College Beijing 100730, 
      China.
FAU - Wang, Yanyu
AU  - Wang Y
AD  - Department of Liver Surgery, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College Beijing 100730, 
      China.
FAU - Wang, Shanshan
AU  - Wang S
AD  - Department of Liver Surgery, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College Beijing 100730, 
      China.
FAU - Xue, Jingnan
AU  - Xue J
AD  - Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Zunyi 
      Medical University Zunyi, Guizhou, China.
FAU - Zhang, Nan
AU  - Zhang N
AD  - Department of Liver Surgery, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College Beijing 100730, 
      China.
FAU - Yang, Xiaobo
AU  - Yang X
AD  - Department of Liver Surgery, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College Beijing 100730, 
      China.
FAU - Lu, Zhenhui
AU  - Lu Z
AD  - Hepatobiliary and Pancreatic Surgery, Shenzhen Qianhai Shekou Free Trade Zone 
      Hospital Shenzhen, Guangdong, China.
FAU - Zhou, Jinxue
AU  - Zhou J
AD  - Department of Hepatopancreatobiliary Surgery, The Affiliated Tumor Hospital of 
      Zhengzhou University Zhengzhou, Henan, China.
FAU - Zhou, Kang
AU  - Zhou K
AD  - Department of Radiology, Peking Union Medical College Hospital, Chinese Academy 
      of Medical Sciences and Peking Union Medical College Beijing 100730, China.
FAU - Sang, Xinting
AU  - Sang X
AD  - Department of Liver Surgery, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College Beijing 100730, 
      China.
FAU - Zhao, Haitao
AU  - Zhao H
AD  - Department of Liver Surgery, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College Beijing 100730, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20230315
PL  - United States
TA  - Am J Cancer Res
JT  - American journal of cancer research
JID - 101549944
PMC - PMC10077043
OTO - NOTNLM
OT  - Advanced biliary tract cancer
OT  - lenvatinib
OT  - local-regional therapy
OT  - synergic effect
OT  - toripalimab
COIS- None.
EDAT- 2023/04/11 06:00
MHDA- 2023/04/11 06:01
PMCR- 2023/03/15
CRDT- 2023/04/10 04:04
PHST- 2022/11/08 00:00 [received]
PHST- 2023/02/19 00:00 [accepted]
PHST- 2023/04/11 06:01 [medline]
PHST- 2023/04/10 04:04 [entrez]
PHST- 2023/04/11 06:00 [pubmed]
PHST- 2023/03/15 00:00 [pmc-release]
PST - epublish
SO  - Am J Cancer Res. 2023 Mar 15;13(3):1026-1037. eCollection 2023.